Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

KENILWORTH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir (SCH 503034), the company's investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States.

PEGINTRON

Clinical investigators will present findings at DDW from numerous PEGINTRON studies evaluating patient response to therapy at certain treatment milestones, an approach that is aimed at individualizing treatment for patients. Schering-Plough also is exploring novel therapeutic approaches with PEGINTRON in combination with investigational antiviral agents to optimize treatment for patients with more difficult-to-treat forms of the disease, such as patients who were nonresponders to previous therapy.

Boceprevir (SCH 503034)

Schering-Plough is undertaking a large, fully integrated clinical development program for its oral HCV protease inhibitor boceprevir, with the goal of developing new strategies for improving treatment outcomes for patients with hepatitis C.

At DDW, Schering-Plough will present results of in vitro studies conducted in collaboration with Wyeth/ViroPharma of boceprevir in combination with their investigational non-nucl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/6/2015)... FOREST, Ill. , March 6, 2015   Hospira, ... the U.S. Food and Drug Administration (FDA) on today,s FDA ... States . This is a watershed moment for improving ... As a leading global provider of biosimilars, Hospira has seen ... we are a proud participant in these early stages of ...
(Date:3/6/2015)... -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted ... announced that James A. Joyce , Aethlon Medical ... at the 27th Annual ROTH Conference on March 10, ... scheduled to present at 5:30 pm Pacific on March ... The Ritz-Carlton Hotel in Laguna Niguel, California ...
(Date:3/6/2015)... , March 6, 2015 Troyen A. ... Officer of CVS Health (NYSE: CVS ), ... in Washington, D.C. today.  Brennan ... role in addressing health care cost and quality as ... making CVS/pharmacy the first national pharmacy chain to stop ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3
... , March 23 The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim ( Germany ) ... ... ... ...
... medical device companies, today announced it has been selected by the Advanced Medical Technology Association (AdvaMed), as a member of the organization,s Business Solutions Program. , ... , ... ... ...
Cached Medicine Technology:Novalung Records 50% Growth 2Novalung Records 50% Growth 3AdvaMed Selects Prolifiq as Member of Business Solutions Program 2AdvaMed Selects Prolifiq as Member of Business Solutions Program 3AdvaMed Selects Prolifiq as Member of Business Solutions Program 4
(Date:3/6/2015)... Pokemini ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Mallory Sofastaii, a ... review and shared with viewers how this is a fully ... years, mobile games have benefited from building in a social ... users to connect their games to Facebook, see what level ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Saving Moses, ... around the world is traveling to Angola, Africa March ... of their malnutrition program. , This will be the ... in Angola, demonstrating their commitment to the region’s population ... The team will engage with the mothers and babies ...
(Date:3/6/2015)... Ticket Down is a reputable source for authentic ... Center. After being away from the touring business for ... of letting up on his “Garth Brooks World Tour.” The ... Yearwood, to venues around the United States. The duo recently ... to the Moda Center in Portland, OR. The husband and ...
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... 2015 As the Muscular Dystrophy Association ... the organization has hired two new Scientific Program Officers, ... will report to Grace Pavlath, Ph.D, who joined MDA ... Program Director, and together will lead MDA as it ... cures for various types of neuromuscular and motor neuron ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4
... ... offers a safe, gentle blend of natural active ingredients that provides temporary relief from common ... ... is in the air. This means itchy eyes, runny nose and sneeze-fests for millions of ...
... ... label. , ... (PRWEB) March 29, 2010 -- Advercan ( www.ADVERCAN.com ), 3M, and its sourcing ally, ... in 2007, and other interested media and beverage companies around Atlanta with very positive ...
... has positive effects, researchers say , MONDAY, March 29 (HealthDay ... people, Swedish researchers have found. , The study included 18 ... to cancer. They were offered a 25-minute hand or foot ... whether to have their massages at home, work or in ...
... ... are to offer Allergan implants as part of their standard breast augmentation package. ... (PRWEB) March 29, 2010 -- ... their ongoing attempt to provide the most comprehensive service to their patients having breast ...
... Payne Bolton School of Nursing at Case Western Reserve University ... cardiac rehabilitation program following a heart attack, bypass surgery or ... their hearts healthy. Women across the age ... comparison to men. Although all groups had a decline between ...
... , This release is available in ... may someday contain less fat and fewer calories, thanks ... as Mukti Singh. She,s based at the ARS National ... In experiments at her Peoria laboratory, Singh is ...
Cached Medicine News:Health News:New Natural Allergy Relief Available 2Health News:New Natural Allergy Relief Available 3Health News:Billions of Cleaner Beverage Can Tops Used as Billboard Space 2Health News:Rubicon Medical To Offer Allergan Implants In Breast Enlargement Surgery 2Health News:Study from CWRU Nursing School finds a year after cardiac event only 37 percent still exercising 2
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Concentrate System is a point-of-care system designed ... (also referred to as Platelet Rich Plasma ... from a small sample of blood. The ... factors, which are found in the platelets. ...
... II Platelet Concentrate System is a point-of-care ... Platelet Concentrate (also referred to as Platelet ... Plasma (PPP) from a small sample of ... body's natural growth factors, which are found ...
... Autologous growth factors (AGF) ... blood, the AGF gel delivers ... growth factors and proteins in ... the information of new bone ...
Medicine Products: